Literature DB >> 10568506

The methylation status of cytosines in a tau gene promoter region alters with age to downregulate transcriptional activity in human cerebral cortex.

H Tohgi1, K Utsugisawa, Y Nagane, M Yoshimura, M Ukitsu, Y Genda.   

Abstract

Changes with age in the methylation status of cytosines in a promoter region of the tau gene were investigated in autopsy human cerebral cortex, using the bisulfite method, polymerase chain reaction (PCR) and direct sequencing of PCR products. While the total number of methylcytosines decreased with age, the changes in methylation status differed among transcription factor binding sites. Cytosines in the AP2-binding sites were never methylated in any of the cases studied at any age. Methylcytosines in the binding sites for Sp1, a transcriptional activator, significantly increased with age, whereas those in the binding sites for GCF, a repressor of GC-rich promoters, significantly decreased with age. These findings suggest that the methylation status of cytosines in the promoter region of the tau gene alters with age to decrease its transcriptional activity in the human cerebral cortex.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10568506     DOI: 10.1016/s0304-3940(99)00731-4

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  21 in total

1.  Formaldehyde, Epigenetics, and Alzheimer's Disease.

Authors:  Fei Wang; Danqi Chen; Peipei Wu; Catherine Klein; Chunyuan Jin
Journal:  Chem Res Toxicol       Date:  2019-04-19       Impact factor: 3.739

Review 2.  Alzheimer's disease and environmental exposure to lead: the epidemiologic evidence and potential role of epigenetics.

Authors:  Kelly M Bakulski; Laura S Rozek; Dana C Dolinoy; Henry L Paulson; Howard Hu
Journal:  Curr Alzheimer Res       Date:  2012-06       Impact factor: 3.498

3.  Does SCFD1 rs10139154 Polymorphism Decrease Alzheimer's Disease Risk?

Authors:  Polyxeni Stamati; Vasileios Siokas; Athina-Maria Aloizou; Emmanouil Karampinis; Stylianos Arseniou; Valerii N Rakitskii; Aristidis Tsatsakis; Demetrios A Spandidos; Illana Gozes; Panayiotis D Mitsias; Dimitrios P Bogdanos; Georgios M Hadjigeorgiou; Efthimios Dardiotis
Journal:  J Mol Neurosci       Date:  2019-07-02       Impact factor: 3.444

Review 4.  Advances in epigenetics and epigenomics for neurodegenerative diseases.

Authors:  Irfan A Qureshi; Mark F Mehler
Journal:  Curr Neurol Neurosci Rep       Date:  2011-10       Impact factor: 5.081

Review 5.  Epigenetic pathways through which experiences become linked with biology.

Authors:  Patrick O McGowan; Tania L Roth
Journal:  Dev Psychopathol       Date:  2015-05

Review 6.  Epigenomics of Alzheimer's disease.

Authors:  David A Bennett; Lei Yu; Jingyun Yang; Gyan P Srivastava; Cristin Aubin; Philip L De Jager
Journal:  Transl Res       Date:  2014-05-16       Impact factor: 7.012

Review 7.  Epigenetic mechanisms in Alzheimer's disease.

Authors:  Diego Mastroeni; Andrew Grover; Elaine Delvaux; Charisse Whiteside; Paul D Coleman; Joseph Rogers
Journal:  Neurobiol Aging       Date:  2011-04-11       Impact factor: 4.673

Review 8.  Epigenetics in Alzheimer's Disease: Perspective of DNA Methylation.

Authors:  Talal Jamil Qazi; Zhenzhen Quan; Asif Mir; Hong Qing
Journal:  Mol Neurobiol       Date:  2017-01-14       Impact factor: 5.590

9.  Genome-wide DNA methylation differences between late-onset Alzheimer's disease and cognitively normal controls in human frontal cortex.

Authors:  Kelly M Bakulski; Dana C Dolinoy; Maureen A Sartor; Henry L Paulson; John R Konen; Andrew P Lieberman; Roger L Albin; Howard Hu; Laura S Rozek
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

Review 10.  Epigenetics of Aging and Alzheimer's Disease: Implications for Pharmacogenomics and Drug Response.

Authors:  Ramón Cacabelos; Clara Torrellas
Journal:  Int J Mol Sci       Date:  2015-12-21       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.